✦ LIBER ✦

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

✍ Scribed by Anforth, R.M.; Blumetti, T.C.M.P.; Kefford, R.F.; Sharma, R.; Scolyer, R.A.; Kossard, S.; Long, G.V.; Fernandez-Peñas, P.

Book ID: 119833708
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 564 KB
Volume: 167
Category: Article
ISSN: 0007-0963
DOI: 10.1111/j.1365-2133.2012.11155.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Trial (BREAK-2) of the BRAF Inh

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

✍ Ascierto, P. A.; Minor, D.; Ribas, A.; Lebbe, C.; O'Hagan, A.; Arya, N.; Guckert 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 182 KB

Detection of Mutant BRAF Alleles in the

Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma

✍ Yancovitz, Molly; Yoon, Joanne; Mikhail, Maryann; Gai, Weiming; Shapiro, Richard 📂 Article 📅 2007 🏛 American Society for Investigative Pathology 🌐 English ⚖ 255 KB

Patient perception of the benefit of a B

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

✍ Grob, J.- J.; Amonkar, M. M.; Martin-Algarra, S.; Demidov, L. V.; Goodman, V.; G 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 223 KB

Dabrafenib in patients with Val600Glu or

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

✍ Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascie 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 259 KB

Sequencing of BRAF inhibitors and ipilim

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

✍ Paolo A Ascierto, Ester Simeone, Diana Giannarelli, Antonio M Grimaldi, Anna Rom 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 210 KB

The Cutaneous Side Effects of Selective

The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma

✍ Lisa Pappas-Taffer, Misha Rosenbach, Emily Y. Chu 📂 Article 📅 2013 🏛 Current Science Inc. 🌐 English ⚖ 519 KB